- 期刊
Terbutaline Solution噴霧治療小兒急性氣喘之臨床評估
Nebulizing Terbutaline Therapy in Children with Acute Asthma
摘要
自民國七十八年七月初至十二月底，經由門診或急診隨意挑選患有急性氣喘之病童，共21位。年齡由一歲七個月至十歲（平均6.2歲），男性13位，女性8位。以terbutaline solutions 5 mg/dose，利用超音波噴霧器給藥，在治療前及治療後十分鐘測量每一病童之呼吸速率、血壓、脈搏，最大呼氣流量及clinical severity score，並作比較。比較結果顯示21位病童治療前及治療後的呼吸速率，最大呼氣流量及clinical severity score在統計學上均有明顯的改善（P值分別小於0.05，0.0005及0.0001），而脈搏及血壓則無明顯差異（P值均大於0.05）。本研究結果告訴我們以超音波噴霧器給予terbutaline solution治療小兒急性氣喘發作為一有效且快速的方法，且沒有心速過快，血壓上升等副作用，可做為治療小兒急性氣喘的第一線用藥。
關鍵字
無資料並列摘要
To evaluate the therapeutic effect of nebulized terbutaline in children with acute asthma, 21 children, aged 1 year and 7 months to 10 years, with acute asthma, were enrolled into this study, during the period from July to December 1989. Each patient received nebulized terbutaline (Bricanyl) 5 mg/dose over 10 minutes. The respiratory rate, pulse rate, blood pressure, peak expiratory flow rate and clinical severity score were recorded before, and at 10 minutes after treatment. Comparing with the data before treatment, respiratory rate, peak expiratory flow rate and clinical severity score at 10 minutes after treatment showed significant improvement (p value ＜0.05; ＜0.0005; ＜0.0001, respetively), but pulse rate and blood pressure did not differ significantly. It was concluded that administration of nebulized terbutaline, at a dose of 5 mg, was both safe and effective in treating acute asthma, and may be used as the first line measure in treating acute asthma in children.